Terms: = Breast cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Prognosis
124 results:
1. The fbxw7-binding sites on FAM83D are potential targets for cancer therapy.
Jiang X; Wang Y; Guo L; Wang Y; Miao T; Ma L; Wei Q; Lin X; Mao JH; Zhang P
Breast Cancer Res; 2024 Mar; 26(1):37. PubMed ID: 38454442
[TBL] [Abstract] [Full Text] [Related]
2. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer.
Treekitkarnmongkol W; Solis LM; Sankaran D; Gagea M; Singh PK; Mistry R; Nguyen T; Kai K; Liu J; Sasai K; Jitsumori Y; Liu J; Nagao N; Stossi F; Mancini MA; Wistuba II; Thompson AM; Lee JM; Cadiñanos J; Wong KK; Abbott CM; Sahin AA; Liu S; Katayama H; Sen S
Sci Signal; 2024 Mar; 17(826):eadh4475. PubMed ID: 38442201
[TBL] [Abstract] [Full Text] [Related]
3. fbxw7 suppresses carcinogenesis and stemness in triple-negative breast cancer through CHD4 degradation and Wnt/β-catenin pathway inhibition.
Xiao G; Lu W; Yuan J; Liu Z; Wang P; Fan H
J Transl Med; 2024 Jan; 22(1):99. PubMed ID: 38268032
[TBL] [Abstract] [Full Text] [Related]
4. [New treatment options in system therapy for breast carcinoma and associated new side effects].
Landin J; Weber WP; Vetter M
Ther Umsch; 2023 Oct; 80(8):353-358. PubMed ID: 37971525
[TBL] [Abstract] [Full Text] [Related]
5. The breast Microbiome in breast cancer Risk and Progression: A Narrative Review.
Peters BA; Kelly L; Wang T; Loudig O; Rohan TE
Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):9-19. PubMed ID: 37943168
[TBL] [Abstract] [Full Text] [Related]
6. Cystic encapsulated papillary carcinoma with ductal carcinoma in situ in the male breast: a clinicopathologic feature with a diagnostic challenge: A case report and review of literature.
Wang B; Wang L; Zhao Z; Xu X
Medicine (Baltimore); 2023 Nov; 102(44):e34388. PubMed ID: 37933028
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.
Cai Z; Shi Q; Li Y; Jin L; Li S; Wong LL; Wang J; Jiang X; Zhu M; Lin J; Wang Q; Yang W; Liu Y; Zhang J; Gong C; Yao H; Yao Y; Liu Q
Sci Adv; 2023 Oct; 9(40):eadi3821. PubMed ID: 37801505
[TBL] [Abstract] [Full Text] [Related]
8. The Role of fbxw7 in Gynecologic Malignancies.
Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
Cells; 2023 May; 12(10):. PubMed ID: 37408248
[TBL] [Abstract] [Full Text] [Related]
9. Blood Oxylipin Profiles as Markers of Oncological Diseases.
Chistyakov DV; Kovalenko LV; Donnikov MY; Sergeeva MG
Biochemistry (Mosc); 2023 May; 88(5):621-629. PubMed ID: 37331708
[TBL] [Abstract] [Full Text] [Related]
10. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract] [Full Text] [Related]
11. B7-H7: A potential target for cancer immunotherapy.
Su Q; Du J; Xiong X; Xie X; Wang L
Int Immunopharmacol; 2023 Aug; 121():110403. PubMed ID: 37290327
[TBL] [Abstract] [Full Text] [Related]
12. First diagnosed invasive lobular carcinoma of the breast combined with gastric metastasis and bone metastasis: a case report and review of the literature.
Sun L; Liu J; Guo M; Xu J; Wang D
BMC Womens Health; 2023 Mar; 23(1):133. PubMed ID: 36966290
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of breast Metastasis from Renal Cell Carcinoma].
Kawamata A; Emi A; Fujimoto M; Kai A; Suzuki E; Kobayashi Y; Sasada S; Masumoto N; Kadoya T; Okada M
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1891-1892. PubMed ID: 36733034
[TBL] [Abstract] [Full Text] [Related]
14. Isolated splenic metastases from rectal carcinoma 5 years after surgery: Case report.
Xu J; He Y; Cai Y; Huang Y; He Y
Medicine (Baltimore); 2023 Jan; 102(2):e32493. PubMed ID: 36637961
[TBL] [Abstract] [Full Text] [Related]
15. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
Hemminki K; Försti A; Liska V; Kanerva A; Hemminki O; Hemminki A
Int J Cancer; 2023 May; 152(9):1837-1846. PubMed ID: 36571455
[TBL] [Abstract] [Full Text] [Related]
16. Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials.
Sauerbrei W; Royston P
BMC Med Res Methodol; 2022 Apr; 22(1):98. PubMed ID: 35382744
[TBL] [Abstract] [Full Text] [Related]
17. TARBP2 Suppresses Ubiquitin-Proteasomal Degradation of HIF-1α in breast cancer.
Li JN; Chen PS; Chiu CF; Lyu YJ; Lo C; Tsai LW; Wang MY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008634
[TBL] [Abstract] [Full Text] [Related]
18. miR-223-3p targets fbxw7 to promote epithelial-mesenchymal transition and metastasis in breast cancer.
Wang Y; Shi S; Wang Y; Zhang X; Liu X; Li J; Li P; Du L; Wang C
Thorac Cancer; 2022 Feb; 13(3):474-482. PubMed ID: 34953047
[TBL] [Abstract] [Full Text] [Related]
19. breast cancer Prevention: Time for Change.
Chlebowski RT; Aragaki AK; Pan K
JCO Oncol Pract; 2021 Dec; 17(12):709-716. PubMed ID: 34319769
[TBL] [Abstract] [Full Text] [Related]
20. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.
Schaafsma E; Zhang B; Schaafsma M; Tong CY; Zhang L; Cheng C
Breast Cancer Res; 2021 Jul; 23(1):74. PubMed ID: 34274003
[TBL] [Abstract] [Full Text] [Related]
[Next]
